Sugi Predict

Sugi Predict / Compounds / SCHEMBL9376409

SCHEMBL9376409

SCHEMBL9376409

NS(=O)(=O)c1cccc(F)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 14/20 0.38
▸ CA1 P00915 12/20 0.38
▸ CA9 Q16790 10/20 0.36
▸ CA12 O43570 10/20 0.36
▸ CA4 P22748 5/20 0.36
▸ CA7 P43166 5/20 0.36
▸ CA14 Q9ULX7 5/20 0.36
▸ CA13 Q8N1Q1 4/20 0.36
▸ CA6 P23280 3/20 0.36
▸ CA5A P35218 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CA3 P07451 1/20 0.34
▸ PLA2G7 Q13093 1/20 0.34
▸ CA5B Q9Y2D0 1/20 0.34
▸ PTGS1 P23219 1/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566637 1.00 CA2 (0.38) CA2CA1CA9CA12CA4
SCHEMBL9180744 0.78 CASR (0.37) PTGS1PTGS2
SCHEMBL29624220 0.78 ALDH1A1 (0.44) —
SCHEMBL2411865 0.78 ALDH1A1 (0.44) —
SCHEMBL12319048 0.78 LOX (0.41) MAPK1PTGS2LMNA
SCHEMBL9177462 0.77 CASR (0.36) PTGS1PTGS2
SCHEMBL9176747 0.77 PTPN1 (0.32) PTGS1PTGS2
SCHEMBL17647899 0.76 NOS3 (0.43) CA2CA1CA9CA12CA4
SCHEMBL22163647 0.75 PTGS1 (0.33) PTGS1PTGS2
SCHEMBL6501463 0.74 CYP3A4 (0.43) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4218754-B1 VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMA (US) 2026-03-25 — — EP disclosed
US-20260008779-A1 CRYSTALLINE FORMS OF CFTR MODULATORS VERTEX PHARMA (US) 2026-01-08 — — US disclosed
US-20250288563-A1 METHODS OF TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INCORPORATED 2025-09-18 — — US disclosed
EP-3880197-B9 METHODS OF TREATMENT FOR CYSTIC FIBROSIS VERTEX PHARMA (US) 2025-07-02 — — EP disclosed
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-26 — — US disclosed
WO-2025129104-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC. (US) 2025-06-19 — — WO disclosed
US-12319693-B2 Crystalline forms of CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-03 — — US disclosed
US-20250051326-A1 CRYSTALLINE FORMS OF CFTR MODULATORS VERTEX PHARMACEUTICALS INCORPORATED 2025-02-13 — — US disclosed
US-12186306-B2 Methods of treatment for cystic fibrosis VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-01-07 — — US disclosed
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-12-17 — — US disclosed
WO-2011094953-A1 COMPOUNDS FOR THE TREATMENT AND PREVENTION OF INFLUENZA F. HOFFMANN-LA ROCHE AG (CH) 2011-08-11 — — WO disclosed
EP-0314505-B1 Herbicidal pyridine sulfonylureas DU PONT (US) 1994-02-16 — — EP disclosed
US-5137886-A Agriculture IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-08-11 — — US disclosed
US-5032166-A Pre and postemergent E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-07-16 — — US disclosed
EP-0433001-A1 Insecticidal compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-06-19 — — EP disclosed
US-4987141-A DERIVATIVES OF BENZENE OR PYRIDINE HAVING SULFONATE AND SULFENYL, SULFONIMIDE OR SULFONAMIDE GROUPS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-01-22 — — US disclosed
US-4946494-A PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1990-08-07 — — US disclosed
CN-1042144-A Pesticidal compound ICI PLC (GB) 1990-05-16 — — CN disclosed
EP-0356029-A2 Insecticidal compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1990-02-28 — — EP disclosed
EP-0314505-A2 Herbicidal pyridine sulfonylureas E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051326-A1 CRYSTALLINE FORMS OF CFTR MODULATORS CFTR, SLC26A4, AQP1 CA2 498/4885CA1 2972/4885CA9 1579/4885
US-12186306-B2 Methods of treatment for cystic fibrosis CFTR, SLC26A4, SCNN1B CA2 580/4885CA1 4396/4885CA9 2170/4885
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 CA2 1067/4885CA1 4843/4885CA9 2705/4885
US-20260008779-A1 CRYSTALLINE FORMS OF CFTR MODULATORS CFTR, SLC26A4, SLC26A3 CA2 352/4885CA1 3803/4885CA9 494/4885
US-12319693-B2 Crystalline forms of CFTR modulators CFTR, SLC26A4, AQP1 CA2 498/4885CA1 2972/4885CA9 1579/4885
US-12168009-B2 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1B, SLC26A4 CA2 1067/4885CA1 4843/4885CA9 2705/4885
US-20250288563-A1 METHODS OF TREATMENT FOR CYSTIC FIBROSIS CFTR, SLC26A4, SCNN1B CA2 580/4885CA1 4396/4885CA9 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.